Double Blind Placebo Study of JARDIANCE® (Empagliflozin) in Prehypertensives Type II Diabetics
Unknown status
Aristotle University Of Thessaloniki
Phase 4
2016-01-01
Objectives:
Primary
1. Primary prevention of new onset of hypertension
Secondary
1. Reduction of 24h BP in type II diabetics with prehypertension
2. Reduction of non dipping status, day and nighttime BP, morning BP surge in subjects
receiving EMPAGLIFLOZIN
3. Reduction in the total cardiovascular risk
4. 3 years morbidity and mortality rates
5. Arterial de-stiffening, reduction in central aortic blood pressure in subjects receiving
EMPAGLIFLOZIN
Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes
Completed
Eli Lilly and Company
Phase 3
2010-07-01
The objective of the current study is to investigate the efficacy, safety and tolerability of
two doses of BI 10773 compared to placebo given for 24 weeks as add-on therapy to metformin
or metformin plus sulfonylurea in patients with Typ 2 Diabetes Mellitus with insufficient
glycaemic control.
Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes
Completed
Boehringer Ingelheim
Phase 3
2010-07-01
The objective of the current study is to investigate the efficacy, safety and tolerability of
two doses of BI 10773 compared to placebo given for 24 weeks as add-on therapy to metformin
or metformin plus sulfonylurea in patients with Typ 2 Diabetes Mellitus with insufficient
glycaemic control.
Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 Diabetes
Completed
Eli Lilly and Company
Phase 3
2010-08-01
This is a pivotal phase III study, mandatory to seek approval by regulatory authorities for
BI 10773 as an anti-diabetic agent compared to an active comparator in patients with type 2
diabetes mellitus and insufficient glycaemic control.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
